Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Open Access Research article

Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis

Angela Pakozdi1, Mohammad A Amin1, Christian S Haas1, Rita J Martinez1, G Kenneth Haines2, Lanie L Santos3, Eric F Morand3, John R David4 and Alisa E Koch15*

Author Affiliations

1 University of Michigan Medical School, 109 Zina Pitcher Place, Ann Arbor, MI 48109, USA

2 Northwestern University Feinberg School of Medicine, 251 E. Huron Street, Chicago, IL 60611, USA

3 Monash University Department of Medicine, Monash Medical Centre, Locked Back No 29, Clayton VIC 3168, Australia

4 Harvard School of Public Health, Boston, 665 Huntington Avenue, Boston, MA 02115, USA

5 VA Medical Service, Department of Veterans Affairs, 2215 Fuller Road, Ann Arbor, MI 48105, USA

For all author emails, please log on.

Arthritis Research & Therapy 2006, 8:R132  doi:10.1186/ar2021

Published: 26 July 2006

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by destruction of bone and cartilage, which is mediated, in part, by synovial fibroblasts. Matrix metalloproteinases (MMPs) are a large family of proteolytic enzymes responsible for matrix degradation. Macrophage migration inhibitory factor (MIF) is a cytokine that induces the production of a large number of proinflammatory molecules and has an important role in the pathogenesis of RA by promoting inflammation and angiogenesis.

In the present study, we determined the role of MIF in RA synovial fibroblast MMP production and the underlying signaling mechanisms. We found that MIF induces RA synovial fibroblast MMP-2 expression in a time-dependent and concentration-dependent manner. To elucidate the role of MIF in MMP-2 production, we produced zymosan-induced arthritis (ZIA) in MIF gene-deficient and wild-type mice. We found that MMP-2 protein levels were significantly decreased in MIF gene-deficient compared with wild-type mice joint homogenates. The expression of MMP-2 in ZIA was evaluated by immunohistochemistry (IHC). IHC revealed that MMP-2 is highly expressed in wild-type compared with MIF gene-deficient mice ZIA joints. Interestingly, synovial lining cells, endothelial cells, and sublining nonlymphoid mononuclear cells expressed MMP-2 in the ZIA synovium. Consistent with these results, in methylated BSA (mBSA) antigen-induced arthritis (AIA), a model of RA, enhanced MMP-2 expression was also observed in wild-type compared with MIF gene-deficient mice joints. To elucidate the signaling mechanisms in MIF-induced MMP-2 upregulation, RA synovial fibroblasts were stimulated with MIF in the presence of signaling inhibitors. We found that MIF-induced RA synovial fibroblast MMP-2 upregulation required the protein kinase C (PKC), c-jun N-terminal kinase (JNK), and Src signaling pathways. We studied the expression of MMP-2 in the presence of PKC isoform-specific inhibitors and found that the PKCĪ“ inhibitor rottlerin inhibits MIF-induced RA synovial fibroblast MMP-2 production. Consistent with these results, MIF induced phosphorylation of JNK, PKCĪ“, and c-jun. These results indicate a potential novel role for MIF in tissue destruction in RA.